Table 3.

Associations Between Inflammatory Biomarkers and Clinicopathological Characteristics

Variables	NLR			LMR			CAR
	Low	High	P value	Low	High	P value	Low	High	P value
Age (years)
<55	36	60		51	45		62	34
≥55	54	62	0.184	57	59	0.563	84	32	0.220
Primary site
Upper inner	11	11		11	11		18	4
Lower inner	19	15		14	20		27	7
Upper outer	35	48		40	43		57	26
Lower outer	14	24		22	16		22	16
Other sites	11	24	0.262	21	14	0.487	22	13	0.184
Tumor size
<2cm	28	39		29	38		46	21
≥2cm,<5cm	40	42		44	38		57	25
>5cm	22	41	0.244	35	28	0.309	43	20	0.986
Histological type
Ductal	84	111		96	99		136	59
Lobular	5	8		9	4		7	6
Other	1	3	0.735	3	1	0.235	3	1	0.470
Histological grade
I–II	35	41		35	41		54	22
III–IV	55	81	0.428	73	63	0.287	92	44	0.608
T stage
T1	7	11		8	10		14	4
T2	44	48		58	34		64	28
T3	14	28		23	19		25	17
T4	25	35	0.453	19	41	0.002	43	17	0.455
N stage
N0	6	1		2	5		4	3
N1	22	49		45	26		46	25
N2	44	53		42	55		65	32
N3	18	19	0.018	19	18	0.045	31	6	0.172
Molecular subtype
Luminal B HER2-	19	30		28	21		34	15
Luminal B HER2+	35	36		33	38		58	13
HER2 enriched	17	37		29	25		44	10
Triple negative	19	19	0.159	18	20	0.642	32	6	0.274
ER status
(-)	54	66		61	59		92	28
(+)	36	56	0.391	47	45	0.971	76	16	0.290
PR status
(-)	56	90		78	68		115	31
(+)	34	32	0.073	30	36	0.282	53	13	0.798
HER2 status
(-)	38	49		46	41		66	21
(+)	52	73	0.763	62	63	0.639	102	23	0.311
Ki-67
<14%	32	39		37	34		51	20
≥14%	58	83	0.584	71	70	0.809	95	46	0.509
The number of involved sites of visceral metastases
0	47	59		54	52		80	26
1	7	13		12	8		16	4
>1	36	50	0.733	42	44	0.793	72	14	0.161
The number of involved sites of bone metastases
1	45	56		49	52		84	17
2–3	38	52		44	46		67	23
>3	7	14	0.638	15	6	0.141	17	4	0.326

Note: Bold text, P value < 0.05.

Abbreviations: OS, overall survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; T, tumor; N, lymph node involvement; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CAR, C-reactive protein/albumin ratio.